PT - JOURNAL ARTICLE AU - Suzuki, Satoru AU - Yamanaga, Kenshi AU - Ishii, Masanobu AU - Matsumoto, Erika AU - Kuyama, Naoto AU - Hirakawa, Kyoko AU - Tabata, Noriaki AU - Akasaka, Tomonori AU - Fujisue, Koichiro AU - Hanatani, Shinsuke AU - Arima, Yuichiro AU - Usuku, Hiroki AU - Yamamoto, Eiichiro AU - Oniki, Kentaro AU - Soejima, Hirofumi AU - Saruwatari, Junji AU - Kawano, Hiroaki AU - Jinnouchi, Hideaki AU - Kaikita, Koichi AU - Yasue, Hirofumi AU - Ogawa, Hisao AU - Tsujita, Kenichi TI - Prediabetic Levels of Hyperglycemia as a Predictor of Microvascular Angina with Possible Involvement of Low Levels of High-Density Lipoprotein Cholesterol and Hemoglobin AID - 10.1101/2024.08.09.24311767 DP - 2024 Jan 01 TA - medRxiv PG - 2024.08.09.24311767 4099 - http://medrxiv.org/content/early/2024/08/10/2024.08.09.24311767.short 4100 - http://medrxiv.org/content/early/2024/08/10/2024.08.09.24311767.full AB - Background The management of modifiable risk factors, including conventional risk factors, can play an important role in the treatment for microvascular angina (MVA). The purpose of this study was to clarify the clinical characteristics of MVA in a case-control study, thereby elucidating the pathogenesis and management of MVA.Methods This study enrolled 92 consecutive patients with MVA (39 men, 53 women, mean age 63.2 ±12.1 years) without obstructive coronary artery disease (≥50% stenosis) or acetylcholine-provoked epicardial coronary spasms between 1993 and 2015. This study enrolled 691 age-matched Japanese participants (466 men, 225 women, mean age 62.9 ±11.0 years) without a history of chest pain or cardiovascular diseases between 2006 and 2012 as controls.Results In multivariate logistic regression analysis, elevated haemoglobin A1c (HbA1c) (per 1 mmol/mol), low high-density lipoprotein cholesterol (HDL-C) (per 1mmol/L), and low haemoglobin (Hgb) (per 10×g/L) levels were significantly associated with MVA (odds ratio [OR] 1.07[1.04-1.10], p <0.001; OR 0.13[0.06-0.29], p <0.001; OR 0.56[0.44-0.72], p <0.001, respectively). However, the difference between the prevalence of diabetes in MVA patients vs. the prevalence in controls was not significant. MVA patients without diabetes had significantly higher HbA1c levels than control patients without diabetes (39±4 mmol/mol vs. 34±3 mmol/mol, respectively; p <0.001). These results were also true for patients and controls stratified by sex. A higher prevalence of proteinuria and lower mean corpuscular volume of erythrocytes were found in MVA patients than in controls stratified by sex.Conclusions Hyperglycaemia reflected by mildly elevated HbA1c levels, (i.e., prediabetes) may be a risk factor for MVA. Low levels of HDL-C and Hgb may also be risk factors for MVA. MVA could be one of the systemic manifestations of microvascular diseases. The study may aid in identifying high-risk MVA patients, allowing increased monitoring and treatments for them.What is already known on this topic Microvascular angina (MVA) has been attracting attention of clinical research because MVA can be associated with future cardiovascular events. The management of modifiable risk factors, including conventional risk factors, can play an important role in the treatment of MVA because there is currently no specific treatment of MVA. The purpose of this study was to clarify the clinical characteristics of MVA.What this study adds Hyperglycaemia reflected by mildly elevated haemoglobin A1c levels, (i.e., prediabetes) may be a risk factor for MVA. Low levels of high-density lipoprotein cholesterol and haemoglobin may also be risk factors for MVA. A higher prevalence of proteinuria and lower mean corpuscular volume of erythrocytes were found in MVA patients than in controls stratified by sex.How this study might affect research, practice or policy MVA could be one of the systemic manifestations of microvascular diseases. The study findings may aid in identifying high-risk patients with MVA, allowing increased monitoring and treatments for them.Competing Interest StatementDr. Hisao Ogawa has received remuneration for lectures from AstraZeneca, Bayer Yakuhin, Ltd., Daiichi Sankyo Co., Ltd., Eisai, Kowa Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co., Ltd., Teijin Pharma, JSR, Nxera Pharma. Dr. Koichi Kaikita received grants from Grants-in-Aid for Scientific Research (23K07534) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; received remuneration for lecture from Bayer Yakuhin, Ltd., Daiichi-Sankyo Co., Ltd., Novartis Pharma AG., Otsuka Pharmaceutical Co., Ltd., Bristol-Myers K.K., and Kowa Pharmaceutical Co. Ltd.; received trust research/joint research funds from Bayer Yakuhin, Ltd., and Daiichi-Sankyo Co., Ltd.; and received scholarship fund from Abbott Medical Co., Ltd. Dr. Kenichi Tsujita has received remuneration for lectures from Abbott Medical Co., Ltd, Amgen K.K., Bayer Yakuhin, Ltd., Daiichi Sankyo Co., Ltd., Kowa Pharmaceutical Co. Ltd., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co.,Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., and TERUMO Co, Ltd.; has received trust research/joint research funds from Bayer Yakuhin, Ltd., Bristol-Myers K.K., Daiichi Sankyo Co., Ltd., MOCHIDA PHARMACEUTICAL CO., LTD., Novo Nordisk Pharma Ltd., and PRA Health Sciences.; has received scholarship fund from Abbott Medical Co., Ltd., ITI Co.,Ltd., Boehringer Ingelheim Japan, Otsuka Pharmaceutical Co.,Ltd., and Boston Scientific Japan K.K.; has received Affiliation with Endowed Department from Abbott Japan Co., Ltd., Boston Scientific Japan K.K., Fides-one, Inc., GM Medical Co., Ltd., ITI Co.,Ltd., Kaneka Medix Co., Ltd., NIPRO CORPORATION, TERUMO Co, Ltd., Philips Japan Ltd., Getinge Group Japan K.K., Orbusneich Medical K. K, Abbott Medical Co., Ltd., BIOTRONIK JAPAN,INC, Boston Scientific Japan K.K., Fukuda Denshi Co., Ltd., Japan Lifeline Co.,Ltd., Medtoronic Japan Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., and NIPRO CORPORATION.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted in accordance with the principles contained in the Declaration of Helsinki. The protocol of our study was approved by the ethics committee of the Faculty of Life Sciences, Kumamoto University, and the Japanese Red Cross Kumamoto Hospital Health Care Centre (approval number: 473). We obtained a signed informed consent from each patient and participant. This study is registered at the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN 000043834). Opt-out materials are available through the website: https://kumadai-junnai.com/archives/clinical.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study are available upon reasonable request.